Temsirolimus (Torisel) Special Investigation (Regulatory Post Marketing Commitment Plan)

This study is currently recruiting participants. (see Contacts and Locations)
Verified March 2015 by Pfizer
Information provided by (Responsible Party):
ClinicalTrials.gov Identifier:
First received: August 18, 2011
Last updated: March 4, 2015
Last verified: March 2015

To confirm the safety of the long-term use of TORISEL 25 mg for Intravenous Drip Infusion particularly for the onset of interstitial lung disease from Weeks 25 to 96 after the start of administration.

Condition Intervention Phase
Renal Cell Carcinoma
Drug: Temsirolimus
Phase 4

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Torisel 25mg For Intravenous Drip Infusion Special Investigation - Survey On Long-term Use -

Resource links provided by NLM:

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Response rate (Responsive cases: CR, PR, PD, SD) [ Time Frame: 96 weeks ] [ Designated as safety issue: No ]
  • The onset of interstitial lung disease in long-term use [ Time Frame: 96 weeks ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • The incidence of adverse events in long-term use [ Time Frame: 96 weeks ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 120
Study Start Date: September 2011
Estimated Study Completion Date: August 2016
Estimated Primary Completion Date: August 2016 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Among the cases registered and treated in the Special Investigation, All-case Survey of temsirolimus, those continuously treated with temsirolimus for more than 24 weeks will be included.
Drug: Temsirolimus
The usual adult dosage of this drug is 25 mg as temsirolimus once weekly by intravenous drip infusion for 30 to 60 minutes. The dosage may be appropriately reduced, depending on patient condition.
Other Name: Torisel

Detailed Description:

Implemented as a Drug Use Investigation by Central Registration System


Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Patients treated with Torisel (patients with metastatic and/or radically unresectable or advanced renal cell carcinoma).


Inclusion Criteria:

  • Patients treated with Torisel (patients with metastatic and/or radically unresectable or advanced renal cell carcinoma).
  • Among patients registered and treated in the Special Investigation, All-case Survey of Torisel, those continuously treated with Torisel for more than 24 weeks will be included.

Exclusion Criteria:

  • Patients not administered Torisel.
  • Patients with a history of severe hypersensitivity to temsirolimus, sirolimus derivative, or any of their components and/or derivatives.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01420601

Contact: Pfizer CT.gov Call Center 1-800-718-1021

Kinki University Hospital Recruiting
Osakasayama, Osaka, Japan, 589-8511
Sponsors and Collaborators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
No publications provided

Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT01420601     History of Changes
Other Study ID Numbers: B1771016
Study First Received: August 18, 2011
Last Updated: March 4, 2015
Health Authority: JAPAN:Pharmaceuticals and Medical Devices Agency (PMDA)

Keywords provided by Pfizer:
Long-term use
Regulatory Post Marketing Commitment Plan

Additional relevant MeSH terms:
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antifungal Agents
Antineoplastic Agents
Immunologic Factors
Immunosuppressive Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses

ClinicalTrials.gov processed this record on March 26, 2015